The Clinical Use of Alzheimer's Disease Biomarkers in Patients with Mild Cognitive Impairment: A European Alzheimer's Disease Consortium Survey

被引：13
作者：
Caprioglio, Camilla [1 ,2 ]
Garibotto, Valentina [3 ,4 ,5 ]
Jessen, Frank [6 ,7 ,8 ]
Froelich, Lutz [9 ]
Allali, Gilles [10 ,11 ,12 ]
Assal, Frederic [10 ,11 ]
Frisoni, Giovanni B. [1 ,2 ]
Altomare, Daniele [1 ,2 ]
机构：
[1] Univ Geneva, Lab Neuroimaging Aging LANVIE, Geneva, Switzerland
[2] Geneva Univ Hosp, Geneva Memory Ctr, Geneva, Switzerland
[3] Univ Geneva, Geneva Univ Neuroctr, Lab Neuroimaging & Innovat Mol Tracers NIMTlab, Geneva, Switzerland
[4] Univ Geneva, Fac Med, Geneva, Switzerland
[5] Geneva Univ Hosp, Div Nucl Med & Mol Imaging, Geneva, Switzerland
[6] Univ Cologne, Univ Hosp, Dept Psychiat, Cologne, Germany
[7] Univ Cologne, Med Fac, Cologne, Germany
[8] German Ctr Neurodegenerat Dis DZNE, Bonn, Germany
[9] Heidelberg Univ, Cent Inst Mental Hlth, Dept Geriatr Psychiat, Mannheim, Germany
[10] Geneva Univ Hosp, Dept Clin Neurosci, Div Neurol, Geneva, Switzerland
[11] Fac Med, Geneva, Switzerland
[12] Yeshiva Univ, Albert Einstein Coll Med, Dept Neurol, Div Cognit & Motor Aging, Bronx, NY USA
来源：
JOURNAL OF ALZHEIMERS DISEASE | 2022年 / 89卷 / 02期
基金：
欧盟地平线“2020”; 瑞士国家科学基金会;
关键词：
Alzheimer's disease; amyloid-PET; APOE; biomarkers; cerebrospinal fluid; clinical use; FDG-PET; magnetic resonance imaging; mild cognitive impairment; tau-PET; DIAGNOSIS; RECOMMENDATIONS; DEFINITION; GUIDELINES; UTILITY;
D O I：
10.3233/JAD-220333
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
Background: Recent advances occurred in the field of Alzheimer's disease (AD) biomarkers and the introduction of a research framework grounded on a biomarker-based definition of AD might have fostered an increased clinical use of AD biomarkers. For this reason, an up-to-date depiction of the clinical use of AD biomarkers is needed. Objective: To investigate the clinical use of the main AD biomarkers in patients with mild cognitive impairment (MCI) by examining the beliefs and preferences of professionals (clinicians and biomarker experts) of the European Alzheimer's Disease Consortium (EADC). Methods: 150 professionals filled in an online survey from May to September 2020. The investigated biomarkers were medial temporal lobe atrophy score (MTA) on structural MRI, typical AD (i.e., temporoparietal and posterior cingulate) hypometabolism on FDG-PET, CSF (A(3 42 , p-tau, t-tau), amyloid-PET and tau-PET. Results: The frequency of responders reporting a frequent-to-constant use of MTA (77%) is higher than that of those reporting a frequent-to-constant use of the other AD biomarkers (i.e., CSF: 45%, p = 0.014; FDG-PET: 32%, p < 0.001; amyloid-PET: 8%, p < 0.001; and tau-PET: 2%, p < 0.001). CSF is considered the most valuable biomarker in terms of additional diagnostic value, followed by amyloid-PET, tau-PET, and typical AD hypometabolism on FDG-PET. Conclusion: AD biomarkers are widely used across European memory clinics with a clinical research background for the diagnosis of MCI. Overall, we observed that CSF is currently considered as the most useful biomarker, followed by amyloid-PET.
引用
收藏
页码：535 / 551
页数：17
相关论文
共 30 条
[1]   The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease [J].
Albert, Marilyn S. ;
DeKosky, Steven T. ;
Dickson, Dennis ;
Dubois, Bruno ;
Feldman, Howard H. ;
Fox, Nick C. ;
Gamst, Anthony ;
Holtzman, David M. ;
Jagust, William J. ;
Petersen, Ronald C. ;
Snyder, Peter J. ;
Carrillo, Maria C. ;
Thies, Bill ;
Phelps, Creighton H. .
ALZHEIMERS & DEMENTIA, 2011, 7 (03) :270-279
[2]   Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison [J].
Altomare, Daniele ;
Caprioglio, Camilla ;
Assal, Frederic ;
Allali, Gilles ;
Mendes, Aline ;
Ribaldi, Federica ;
Ceyzeriat, Kelly ;
Martins, Marta ;
Tomczyk, Szymon ;
Stampacchia, Sara ;
Dodich, Alessandra ;
Boccardi, Marina ;
Chicherio, Christian ;
Frisoni, Giovanni B. ;
Garibotto, Valentina .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (07) :2200-2211
[3]   Applying the ATN scheme in a memory clinic population The ABIDE project [J].
Altomare, Daniele ;
de Wilde, Arno ;
Ossenkoppele, Rik ;
Pelkmans, Wiesje ;
Bouwman, Femke ;
Groot, Colin ;
van Maurik, Ingrid ;
Zwan, Marissa ;
Yaqub, Maqsood ;
Barkhof, Frederik ;
van Berckel, Bart N. ;
Teunissen, Charlotte E. ;
Frisoni, Giovanni B. ;
Scheltens, Philip ;
van der Flier, Wiesje M. .
NEUROLOGY, 2019, 93 (17) :E1635-E1646
[4]   Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset [J].
Altomare, Daniele ;
Ferrari, Clarissa ;
Caroli, Anna ;
Galluzzi, Samantha ;
Prestia, Annapaola ;
van der Flier, Wiesje M. ;
Ossenkoppele, Rik ;
Van Berckel, Bart ;
Barkhof, Frederik ;
Teunissen, Charlotte E. ;
Wall, Anders ;
Carter, Stephen F. ;
Scholl, Michael ;
Choo, Il Han ;
Grimmer, Timo ;
Redolfi, Alberto ;
Nordberg, Agneta ;
Scheltens, Philip ;
Drzezga, Alexander ;
Frisoni, Giovanni B. .
JOURNAL OF NEUROLOGY, 2019, 266 (10) :2535-2545
[5]  
[Anonymous], Aducanumab (marketed as Aduhelm) Information
[6]   Clinical Use and Utility of Amyloid Imaging [J].
Barthel, Henryk ;
Sabri, Osama .
JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (11) :1711-1717
[7]   Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey [J].
Bertens, Daniela ;
Vos, Stephanie ;
Kehoe, Patrick ;
Wolf, Henrike ;
Nobili, Flavio ;
Mendonca, Alexandre ;
van Rossum, Ineke ;
Hort, Jacub ;
Luis Molinuevo, Jose ;
Heneka, Michael ;
Petersen, Ron ;
Scheltens, Philip ;
Visser, Pieter Jelle .
ALZHEIMERS RESEARCH & THERAPY, 2019, 11 (01)
[8]   Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease [J].
Blennow, Kaj ;
Dubois, Bruno ;
Fagan, Anne M. ;
Lewczuk, Piotr ;
de Leon, Mony J. ;
Hampel, Harald .
ALZHEIMERS & DEMENTIA, 2015, 11 (01) :58-69
[9]   Do Beliefs about the Pathogenetic Role of Amyloid Affect the Interrpretatrion of Amyloid PET on the clinic? [J].
Boccardi, Marina ;
Altomare, Daniele ;
Ferrari, Clarissa ;
Festari, Cristina ;
Antelmi, Luigi ;
Pievani, Michela ;
Tarallo, Anna ;
Muscio, Cristina ;
Guerra, Ugo P. ;
Paghera, Barbara ;
Padovani, Alessandro ;
Frisoni, Giovanni B. .
NEURODEGENERATIVE DISEASES, 2016, 16 (1-2) :111-117
[10]   The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey [J].
Bocchetta, Martina ;
Galluzzi, Samantha ;
Kehoe, Patrick Gavin ;
Aguera, Eduardo ;
Bernabei, Roberto ;
Bullock, Roger ;
Ceccaldi, Mathieu ;
Dartigues, Jean-Francois ;
de Mendonca, Alexandre ;
Didic, Mira ;
Eriksdotter, Maria ;
Felician, Olivier ;
Froelich, Lutz ;
Gertz, Hermann-Josef ;
Hallikainen, Merja ;
Hasselbalch, Steen G. ;
Hausner, Lucrezia ;
Heuser, Isabell ;
Jessen, Frank ;
Jones, Roy W. ;
Kurz, Alexander ;
Lawlor, Brian ;
Lleo, Alberto ;
Martinez-Lage, Pablo ;
Mecocci, Patrizia ;
Mehrabian, Shima ;
Monsch, Andreas ;
Nobili, Flavio ;
Nordberg, Agneta ;
Rikkert, Marcel Olde ;
Orgogozo, Jean-Marc ;
Pasquier, Florence ;
Peters, Oliver ;
Salmon, Eric ;
Sanchez-Castellano, Carmen ;
Santana, Isabel ;
Sarazin, Marie ;
Traykov, Latchezar ;
Tsolaki, Magda ;
Visser, Pieter Jelle ;
Wallin, Asa K. ;
Wilcock, Gordon ;
Wilkinson, David ;
Wolf, Henrike ;
Yener, Goersev ;
Zekry, Dina ;
Frisoni, Giovanni B. .
ALZHEIMERS & DEMENTIA, 2015, 11 (02) :195-206
123